Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...
Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...
BUFFALO, NY - March 21, 2025 – A new editorial was published in Oncotarget, Volume 16, on March 13, 2025, titled “ No disease ...
Zacks.com on MSN13d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCCThe EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or ...
Phase III DIPPER trial shows that adjuvant camrelizumab administered after induction-concurrent chemoradiotherapy ...
China NMPA approves Akeso's penpulimab for first-line treatment of nasopharyngeal cancer: Hong Kong Tuesday, March 18, 2025, 17:00 Hrs [IST] Akeso Inc., a biopharmaceutical compan ...
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...
Two new drugs to treat prostate and liver cancer have been given the green light for use by the NHS in Scotland. The Scottish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback